Novo Nordisk

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novo Nordisk and other ETFs, options, and stocks.

About NVO

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care and Rare Disease segments.

CEO

Maziar Mike Doustdar

CEOMaziar Mike Doustdar

Employees

68,794

Employees68,794

Headquarters

Bagsværd, Capital Region

HeadquartersBagsværd, Capital Region

Founded

1923

Founded1923

Employees

68,794

Employees68,794

NVO Key Statistics

Market cap

196.25B

Market cap196.25B

Price-Earnings ratio

10.21

Price-Earnings ratio10.21

Dividend yield

2.83%

Dividend yield2.83%

Average volume

13.55M

Average volume13.55M

High today

$45.57

High today$45.57

Low today

$43.46

Low today$43.46

Open price

$44.95

Open price$44.95

Volume

9.83M

Volume9.83M

52 Week high

$75.78

52 Week high$75.78

52 Week low

$35.12

52 Week low$35.12

NVO News

Benzinga 3h

Novo Nordisk Data Breach: Hackers Claim To Have Stolen Drug Research, Trial Data And AI Models

FulcrumSec Claims Months-Long Access To Company Systems Citing a message posted by FulcrumSec on Tuesday, Reuters reported that the group spent more than two m...

TipRanks 4h

Novo Nordisk’s Iraq Haemophilia Study Adds Real‑World Support for Turoctocog Alfa

Novo Nordisk (NVO) announced an update on their ongoing clinical study. Unlock powerful investing tools and data-driven insights with TipRanks Premium for more...

TipRanks 4h

Novo Nordisk price target raised to DKK 325 from DKK 300 at Berenberg

Berenberg analyst Kerry Holford raised the firm’s price target on Novo Nordisk (NVO) to DKK 325 from DKK 300 and keeps a Buy rating on the shares. Unlock power...

Analyst ratings

54%

of 37 ratings

Buy

37.8%

Hold

54.1%

Sell

8.1%

More NVO News

Simply Wall St 1d

Novo Nordisk Wins UK Approval For Oral Wegovy In Europe First

The UK has approved Novo Nordisk's oral Wegovy pill for chronic weight management. This is the first oral GLP-1 weight-loss therapy cleared in Europe. The dec...

Nasdaq 1d

Eli Lilly vs. Novo Nordisk: Better Obesity Drug Stock?

Key Points Eli Lilly currently leads the weight loss market. Novo Nordisk's newer launches could help it make up some ground. Both could capitalize on the gr...

Nasdaq 1d

Novo Nordisk A/S is Attracting Investor Attention: Here is What You Should Know

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could i...

TipRanks 2d

Novo Nordisk Seeks China Approval for Wegovy Pill, Intensifying Rivalry with Lilly

Novo Nordisk (NVO) is stepping up its competition with rival Eli Lilly (LLY) in China’s oral weight loss drug market. According to a Reuters report, CEO Mike Do...

TipRanks 2d

Novo Nordisk Expands 2026 Share Buyback, Holding 0.8% of Capital in Treasury Shares

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new invest...

CNBC 4d

Drugmakers race to find a place in the next wave of obesity drugs

Key Points Eli Lilly, Novo Nordisk, Amgen, Zealand, Structure Therapeutics shared their visions for the future of obesity medicine. Drugmakers pitched doctors...

Benzinga 6d

Novo Nordisk Advances Weight-Loss Portfolio With UK Approval Of Wegovy Tablet

The approval gives eligible patients a non-injectable alternative to GLP-1-based weight-loss therapies. MHRA Clears First Oral Wegovy Option According to Novo...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.